Personalised Cancer Immunotherapy
Achilles Therapeutics UK Limited specialises in developing personalised cancer immunotherapy approaches that target tumour-specific mutations. The organisation focuses on creating individualised treatment strategies based on each patient’s unique tumour genomic profile, utilising advanced sequencing technologies to identify clonal neoantigens present across all cancer cells within a tumour.
- Tumour Neoantigen Targeting
- Clonal Mutation Analysis
- Patient-Specific Therapeutic Design
The therapeutic strategy emphasises precision medicine principles, developing treatments tailored to the molecular characteristics of individual malignancies rather than employing standardised protocols.
Advanced Non-Small Cell Lung Cancer
The organisation demonstrates concentrated interest in treating advanced non-small cell lung cancer, particularly in patients who have progressed following standard therapeutic interventions. Research activities encompass both metastatic disease and locally advanced presentations, addressing critical unmet needs in patients with limited treatment options.
- Metastatic NSCLC Treatment
- Post-Chemotherapy Progression Management
- Locally Advanced Disease Intervention
The focus extends to patients who have experienced disease progression after platinum-based chemotherapy and immune checkpoint inhibitor therapy, representing a challenging clinical population with substantial therapeutic resistance.
T Cell-Based Immunotherapy
Achilles Therapeutics UK Limited invests in developing T cell receptor engineered therapies that harness the body’s immune system to recognise and eliminate cancer cells. The approach involves engineering autologous T cells to express receptors capable of identifying tumour-specific antigens, creating a targeted immune response against malignant tissue.
- TCR-Engineered T Cell Products
- Autologous Cell Therapy Development
- Neoantigen-Specific Immune Recognition
This therapeutic modality represents an innovative approach to adoptive cell therapy, designed to overcome limitations of conventional immunotherapeutic strategies by providing highly specific tumour recognition capabilities.
Solid Tumour Immunology
The organisation’s research portfolio emphasises addressing challenges in treating solid tumours, which have historically proven more resistant to immunotherapy compared to haematological malignancies. Investigations focus on overcoming the immunosuppressive tumour microenvironment and enhancing immune cell infiltration into solid malignancies.
- Solid Tumour Immune Evasion
- Tumour Microenvironment Modulation
- Enhanced Immune Cell Trafficking
The therapeutic development programme addresses the complexity of solid tumour biology, seeking to improve treatment outcomes in cancers where traditional immunotherapy approaches have demonstrated limited efficacy.
